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sion is likely if the velocity is more than 3.4 m/s (estimated 
systolic PAP > 50 mmHg) with or without additional vari-
ables [2]. Both underestimation and overestimation of the 
estimated systolic PAP frequently occur.
PAH is a debilitating and progressive disease with a tre-
mendous psychosocial and economic impact for patients. A 
high prevalence of anxiety and depression (up to 40 %) is 
reported in patients with PAH leading to impairment of QoL 
[4]. An increase in clinical severity of the disease is associ-
ated with greater limitations and decrease in QoL. Exercise 
capacity, symptoms of right heart failure, haemodynamic 
characteristics, functional class and also mental disorders 
are associated with QoL. The majority of the studies on QoL 
in PAH patients used different standard generic question-
naires or tools specific for heart or lung diseases, not reflect-
ing the clinical status of patients with PAH—for example 
the Minnesota Living with Heart Failure or the 36-item 
Medical Outcome Study Short-Form Health Survey Ques-
tionnaire (SF-36). Recently, a more disease-specific instru-
ment was designed, the Cambridge PH Outcome Review 
(CAMPHOR) scale [5]. This scale exhibits superior psycho-
metric properties, compared with the SF-36, in the assess-
ment of pulmonary hypertension reported outcome [6].
In the study by Blok et al., almost all patients were on 
monotherapy receiving bosentan during follow-up [1]. In 
the 13 patients in whom the QoL declined during follow-
up, the baseline functional class and exercise capacity were 
significantly worse, indicating more severe disease. No 
haemodynamic data (pulmonary vascular resistance or car-
diac index) at baseline or changes in functional class dur-
ing follow-up were reported. The 5-year survival rate was 
82 % and age, baseline functional class or exercise capacity 
and decline in QoL appeared to be predictors for mortality 
in this study. It is important to know that a decline in QoL 
is associated with worse outcome, i.e. higher mortality in 
In the current issue of The Netherlands Heart Journal, Blok 
et al. describes the quality of life (QoL) in patients with pul-
monary arterial hypertension (PAH) due to congenital heart 
disease (CHD) [1].
In this observational study, 39 out of 85 patients (46 %) 
with PAH-CHD who received PAH-targeted therapy filled 
in the Short-Form Health Survey (SF-36) QoL question-
naire correctly and could be included. Out of these 39 
patients, 50 % had Down syndrome. The diagnosis of PAH 
was based on echocardiography and defined as a tricuspid 
regurgitation velocity of at least 2.9 m/s (estimated systolic 
pulmonary artery pressure (PAP) of 36 mmHg) [1].
PAH is a subgroup of pulmonary hypertension, includ-
ing different forms with the same histopathological changes 
primarily affecting the pulmonary arteries, leading to 
endothelial dysfunction, proliferative changes and vascu-
lar remodelling [2]. The prevalence of PAH is between 15 
and 50 cases per million [3]. The diagnosis should be con-
firmed by right heart catheterisation, and is characterised by 
a mean PAP of at least 25 mmHg at rest and a pre-capillary 
haemodynamic profile including a pulmonary artery wedge 
pressure of less than 15 mmHg and a pulmonary vascular 
resistance of more than 3 Woods Units [2]. Echocardiog-
raphy is used to estimate the systolic PAP based on the 
tricuspid regurgitation peak velocity and the presence of 
additional echocardiographic variables suggestive of pul-
monary hypertension. The presence of pulmonary hyperten-
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PAH-CHD. However, it remains unclear whether the use 
of serial QoL questionnaires is superior or additive to the 
current follow-up strategy of evaluation of functional class, 
biomarkers and exercise capacity.
Besides general measures and supportive therapy, targeted 
PAH therapy is indicated in symptomatic patients with pul-
monary vascular disease and a decreased functional capac-
ity (Modified New York Heart Association functional class 
of at least II) [2, 7]. The medical treatment of PAH is based 
on goal-oriented therapy [2]. The clinical response should 
be reassessed 3–6 months after the initial treatment and is 
based on different parameters or goals, such as: functional 
class, exercise capacity, biomarkers, echocardiography and 
haemodynamic parameters. If there is no improvement, 
sequential combination therapy should be started including 
another class of drugs [2]. Patients who achieve the treat-
ment goals, irrespective of the type of medication used, 
seems to have a better prognosis and QoL. Predictors for 
outcome of PAH are sex, functional class, aetiology of PAH, 
exercise capacity, haemodynamics related to right ventricle 
performance and QoL [8].
CHD patients with an unrestricted pressure and volume 
overload due the presence of an intra- or extra-cardiac shunt 
are at risk for the development of PAH. However, PAH can 
develop at any stage of CHD, in the presence of a left-to-
right shunt but also up to years after a corrective procedure 
[9]. The extreme end of the PAH-CHD spectrum is the Eisen-
menger syndrome, characterised by a reversed (right-to-left) 
or bidirectional shunt with severe cyanosis and multiorgan 
involvement. It is a rare disease and the number of patients 
will decrease in the next decades due to the improvement of 
CHD treatment in recent decades. Recent recommendations 
have stated that the defect should only be repaired if no pul-
monary vascular disease is present, i.e. an indexed pulmo-
nary vascular resistance of less than 4 Woods Units × m2 [10, 
11]. The estimated prevalence of PAH in adults with CHD 
is 10 %, and it has an adverse impact on outcome and QoL 
[12]. Besides PAH-targeted therapy, individualised rehabili-
tation programmes are indicated for PAH-CHD patients to 
improve QoL by enabling participation in social activities 
and to maintain an active lifestyle [2, 11]. Training leads to 
higher levels of physical activity, improved cardiorespira-
tory function and patient-reported QoL [13].
In patients with Down syndrome the prevalence of 
CHD, mainly atrioventricular septal defects, is about 50 %. 
These patients might be more prone to develop PAH com-
pared with non-Down syndrome individuals with the same 
CHD. PAH-specific therapy seems to be safe and leads to 
increased exercise tolerance. However, the validity of mea-
suring exercise capacity and QoL in this specific subgroup 
remains a concern [10].
Current guidelines on adult CHD and pulmonary hyper-
tension recommend that patients with PAH-CHD should be 
followed by tertiary centres combining expertise in CHD 
and PAH in a multidisciplinary approach [2, 11].
Conclusion
PAH related to CHD is a severe disease with a significant 
impact on the QoL, as demonstrated by Blok et al. [1]. It 
appears that the serial measurements of QoL using validated 
questionnaires might be of additive value and a decline in 
QoL seems to be associated with an increased mortality in 
PAH-CHD.
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